Mounjaro in Dubai: Regulatory & Evidence Guide

UAE regulatory context

The UAE national essential medicines list published in 2025 includes tirzepatide dose strengths.^[1] Abu Dhabi's standard for non-surgical management of obesity also places tirzepatide within clinician-managed care.^[2] These documents establish regulatory and clinical context; they do not establish real-time inventory, price, insurance coverage or suitability for a particular person.

Medicine registration, prescribing, reimbursement and stock are separate questions. This article addresses the first and the evidence base. Readers needing medical decisions should use a licensed UAE healthcare professional and current official medicine information.

How tirzepatide works

Tirzepatide activates the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In clinical studies, these pathways affect glucose-dependent insulin secretion, glucagon signaling, gastric emptying, appetite-related signaling and body weight. Mechanism does not, by itself, establish benefit or risk for an individual.

For a receptor-level comparison that includes investigational compounds, see the GLP-1, GIP and glucagon mechanism guide.

SURMOUNT-1 obesity trial

In SURMOUNT-1, adults with obesity or overweight without diabetes were randomized to tirzepatide 5 mg, 10 mg or 15 mg or placebo. At 72 weeks, mean body-weight changes were -15.0%, -19.5% and -20.9% for the three tirzepatide groups and -3.1% for placebo.^[3]

Those are group means from a controlled trial. They are not a personal outcome prediction, dosing recommendation or comparison of UAE care programs.

SURPASS-2 type 2 diabetes trial

SURPASS-2 compared once-weekly tirzepatide 5 mg, 10 mg and 15 mg with semaglutide 1 mg in adults with type 2 diabetes. All three tirzepatide doses were noninferior and superior to semaglutide for mean A1C change at 40 weeks, and mean body-weight reductions were greater in the tirzepatide groups.^[4]

The trial compared specified regimens in a defined population. It does not determine which medicine is appropriate for a particular person or jurisdiction.

Mounjaro is not retatrutide

For the current investigational timeline, use the retatrutide approval tracker. The retatrutide batch-documentation guide explains what those historical COAs can and cannot establish.

What this page intentionally does not provide

• current prices or cost comparisons;
• stock or availability claims;
• seller, pharmacy or clinic links;
• insurance predictions or referral routes;
• dosing, titration, administration or personal treatment advice.